

## Genovis was granted SEK 1 million in research support from VINNOVA.

Genovis has been granted SEK 1 million in research support from VINNOVA (the Swedish Agency for Innovation Systems) to explore a method for online process control in conjunction with manufacturing of the biological drug, mAbCHECK. The project, which is being carried out in collaboration with CapSenze, runs until 2016.

Pharmaceutical companies have a constant need to improve their ability to understand their process parameters and the parameters that give rise to or affect the properties of biological drugs\*. The ultimate goal is to control the process by analyzing the product at different times and adjusting process parameters when necessary to achieve a safe and effective biological drug as the end product.

“In addition to patient safety, the pharmaceutical industry is interested in being able to produce high-quality drugs at the lowest cost possible and the project specifically intends to offer this group a reliable and automatic method that saves both time and money in the customer's optimization of production processes,” says Sarah Fredriksson, CEO at Genovis

*\*Biological drugs are produced in “living” cells, a production system that is far more complex than pure chemical synthesis of small molecules. The industry has a strong incentive to find rapid and automatable solutions to analyze antibodies – preferably one that is fully automated, without any manual intervention.*

For more information, please contact:  
Sarah Fredriksson, CEO, Genovis AB  
T: +46 (0)46-10 12 35  
E: [sarah.fredriksson@genovis.com](mailto:sarah.fredriksson@genovis.com)

### ABOUT GENOVIS

Genovis' business concept is to develop, produce and market innovative technologies that facilitate and enable development of new treatment methods and diagnostics for customers in the medical device and pharmaceutical industries. The Group consists of Genovis AB and the subsidiary GeccoDots AB. Genovis develops and sells unique enzymes (protein engineering portfolio) in innovative product formats that facilitate development and quality control of biological drugs. GeccoDots uses nanotechnology to produce a new type of contrast agent that is used in medical imaging.

*Genovis shares are listed on NASDAQ OMX First North, and Thenberg Fondkommission is Certified Adviser for the Company, t: +46 (0)31-745 50 00*